GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » Total Current Liabilities

Cyfuse Biomedical KK (TSE:4892) Total Current Liabilities : 円648.60 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cyfuse Biomedical KK's total current liabilities for the quarter that ended in Dec. 2024 was 円648.60


Cyfuse Biomedical KK Total Current Liabilities Historical Data

The historical data trend for Cyfuse Biomedical KK's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK Total Current Liabilities Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
206.77 386.29 682.54 666.34 648.60

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 581.46 666.34 568.05 577.72 648.60

Cyfuse Biomedical KK Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Cyfuse Biomedical KK's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=75.185+525.8
+Other Current Liabilities+Current Deferred Liabilities
=47.61+0
=648.60

Cyfuse Biomedical KK's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=75.185+525.8
+Other Current Liabilities+Current Deferred Liabilities
=47.61+0
=648.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Cyfuse Biomedical KK Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyfuse Biomedical KK Business Description

Traded in Other Exchanges
N/A
Address
3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK Headlines

No Headlines